News
News Home
Quick Bites
Exploradio
News Archive
News Channel
Special Features
NPR
nowplaying
On AirNewsClassical
Loading...
  
School Closings
WKSU Support
Funding for WKSU is made possible in part through support from the following businesses and organizations.

Lehmans

Wayside Furniture

Northeast Ohio Medical University


For more information on how your company or organization can support WKSU, download the WKSU Media Kit.

(WKSU Media Kit PDF icon )


Donate Your Vehicle to WKSU

Programs Schedule Make A Pledge Member BenefitsFAQ/HelpContact Us
Health and Medicine




Exploradio: Breast cancer vaccine targets 'retired' protein
A novel approach to cancer prevention teaches the body's immune system to target tumors, but a breast cancer vaccine may be too far outside the box for mainstream funders
by WKSU's JEFF ST. CLAIR
This story is part of a special series.


Reporter / Host
Jeff St. Clair
 
October is breast cancer awareness month. But a Cleveland Clinic researcher has had a hard time attracting research dollars. That is, until local donors stepped in to fund Vincent Tuohy's idea for a breast cancer vaccine.
Courtesy of Richard Taylor Flickr CC
Download (WKSU Only)
In The Region:

A Cleveland scientist has devised a novel approach to treating breast cancer.

But in this week' Exploradio, WKSU' Jeff St.Clair reports that the hardest part of Vincent Tuohy' work has been getting fellow researchers to believe cancer prevention is possible.

 

Exploradio: Breast cancer vaccine

Other options:
Windows Media / MP3 Download (4:18)


Mane of white hair inspires retired proteins

Cleveland Clinic researcher Vincent Tuohy’s inspiration for a breast cancer vaccine came from an unlikely source, "a man with a beautiful mane of white hair.”

It was a true eureka moment, according to Tuohy, because while admiring the man's full head of hair he came up with his, "retired protein hypothesis.”

Tuohy realized that as we age, specific tissues, like the pigment cells in the man’s hair, stop making certain proteins.  “They become retired,” according to Tuohy.

He theorized that if abnormal tissues like tumors produce these retired proteins, they could be targeted by the body's own immune system.

Having spent a carrier studying auto-immune diseases, Tuohy knew T-cells could be trained to recognized retired proteins that often occur in tumor cells, but rarely in healthy tissues, “That’s what cancer vaccines are, they’re auto-immune vaccines.”

He soon found a protein in lactating breast tissue that is not expressed in post-menopausal women, or in women without children.  But breast tumors in the mouse models Tuohy studied do express it.  It’s called alpha-lactalbumin.

 

Targeting alph-lactalbumin in the lab

In his lab, Tuohy gives the fifteen second version of how the lactalbumin protein is made while grad student Justin Johnson shows the proper technique to make vaccines to test in mice. Johnson says it takes around an hour to to get it mixed right.

“We take a gene, we cut the gene, we put it in the vector, we have the vector stuck in the bacteria, the bacteria grow, they make the protein, we purify the protein from the bacteria, and that’s our target protein.”

 The lactalbumin vaccine was tested on mice bred to develop breast cancer at an early age.  Tuohy says the results in the vaccinated mice were dramatic, "none of the mice had tumors at 10 months of age."  But he says in the control mice that were not immunized with the protein, "100 percent of them had tumors.”

The discovery gained international attention in 2010 when Tuohy first published his results in the journal Nature Medicine.  But not all of it positive.

 

“There’s been a lot of pushback.”

Tuohy feels he got the cold shoulder from the cancer research community. He says his idea of targeting retired proteins in tumors was out of their box, "because nobody believed you could make a vaccine that could prevent breast cancer," and he was an from another field.

Tuohy had spent his career studying auto-immune diseases like MS. In his prior research he harnessed the immune system to attack retired cells in other organ systems.  But Tuohy's outsider status has made it hard for him to raise money from major breast cancer funders.  He’s 0-15 in grant requests in the three years since his paper was published.  He says, "I’m doing the best work of my career and I get turned down.

Shield Biotech leads clinical trials

But local supporters, some anonymous, have stepped up to cover the $6 million needed to begin testing Tuohy’s breast cancer vaccine in humans.  Last month the Cleveland Clinic’s business creation arm launched Shield Biotech to manage clinical trials that could cost upwards of $100 million over the next decades.

Tuohy sees his work as the first step in filling a hole in our approach to age related diseases, the lack of a vaccine program for adults.  "It’s ridiculous,” says Tuohy.

He says the research establishment is so focused on cancer treatment, that the idea of cancer prevention has yet to take hold.

“The hardest thing I’ve had to do is not develop the vaccine, [but] convince people that what they thought was impossible is possible.”

Tuohy and his team at the Cleveland Clinic’s Lerner Research Institute are hoping their breast cancer vaccine will pave the way for treating and preventing other diseases. He’s currently developing vaccines targeting retired proteins in prostate, ovarian and other cancers.

(Click image for larger view.)

Add Your Comment
Name:

Location:

E-mail: (not published, only used to contact you about your comment)


Comments:




 
Page Options

Print this page

E-Mail this page / Send mp3

Share on Facebook



Support for Exploradio
provided by:








Stories with Recent Comments

Seven minutes changed everything, but what changed Ashford Thompson?
He shot the guy four times in the head. I have never been that drunk or mad, and I have been through it. Shoot a guy once is bad, maybe a mistake, shoot a guy f...

First cricket farm in the U.S. opens in Youngstown
I am interested in cricket flour to replace soy flour in a low carbohydrate diet. As soon as you have cricket flour available for the average person, please le...

New process starts digesting sludge in Wooster
Awesome! When do our sewage rates decrease accordingly?

Akron's Chapel Hill Mall in foreclosure
Not a surprise. Between the shoplifting, gangs and violence that goes on up there it is no wonder that no one feels safe to shop at Chapel Hill. They have sca...

Ohio launches investigation into at least one Concept charter school
I worked at Noble Academy Cleveland as admin assistant and enrolment coordinator for 6 years, I know this is so valid and true and can provide staff names and p...

Crisis looms in filling aviation industry jobs in Ohio and the nation
I listened to this story yesterday morning on the radio and just want to add this comment. My son went to school to train as an air traffic controller, and gra...

Cuyahoga Valley National Park considers fire to fight invasives
I'm for the controlled burn. There are not enough people (myself included) who volunteer for the removal of invasive plant species. Therefore, another solution ...

Remembering Cleveland music impresario Hank LoConti
The picture here is not the original Agora. It is the old WHK studios where the Agora moved into.

Copyright © 2014 WKSU Public Radio, All Rights Reserved.

 
In Partnership With:

NPR PRI Kent State University

listen in windows media format listen in realplayer format Car Talk Hosts: Tom & Ray Magliozzi Fresh Air Host: Terry Gross A Service of Kent State University 89.7 WKSU | NPR.Classical.Other smart stuff. NPR Senior Correspondent: Noah Adams Living on Earth Host: Steve Curwood 89.7 WKSU | NPR.Classical.Other smart stuff. A Service of Kent State University